PURPOSE: To describe total fatigue (TF) and chronic fatigue (CF) in 476 long-term Hodgkin's disease survivors (HDSs). The development in CF over time was explored in 280 of the patients who had also been assessed 8 years earlier. PATIENTS AND METHODS: In 2003, the Fatigue Questionnaire was mailed to 610 successfully treated HDSs at the Norwegian Radium Hospital from 1971 to 1997. Mean TF scores and occurrence of CF were compared with general population (GP) values. RESULTS: Four hundred seventy-six complete forms (81%) were received (median age, 46 years; 56% males, median follow-up time, 195 months). There was a positive association between age and TF (P < .05), whereas presence of B symptoms at diagnosis and treatment before 1980 were associated with CF. Mean TF scores were elevated in HDSs compared with the GP (mean TF score, 14.6; 95% CI, 14.1 to 15.7 v 12.1; 95% CI, 11.9 to 12.3, respectively; P < .001), as was the proportion of persons with CF (30% v 11%, respectively; odds ratio = 3.6; P < .001). The 70 patients with CF 8 years earlier still reported higher TF at follow-up than the 210 patients without CF at the previous assessment (mean TF score, 17.0; 95% CI, 15.6 to 18.3 v 13.1; 95% CI, 12.9 to 14.1, respectively; P < .001). Significantly more patients with persisting CF had B symptoms at diagnosis compared with patients who had recovered (P = .05). No significant association with treatment modality and intensity was found. CONCLUSION: Fatigue remains a major complaint in HDSs several years after treatment, but the association between treatment and fatigue still remains unclear. Many HDSs may recover from CF, particularly patients without B symptoms at diagnosis.
PURPOSE: To describe total fatigue (TF) and chronic fatigue (CF) in 476 long-term Hodgkin's disease survivors (HDSs). The development in CF over time was explored in 280 of the patients who had also been assessed 8 years earlier. PATIENTS AND METHODS: In 2003, the Fatigue Questionnaire was mailed to 610 successfully treated HDSs at the Norwegian Radium Hospital from 1971 to 1997. Mean TF scores and occurrence of CF were compared with general population (GP) values. RESULTS: Four hundred seventy-six complete forms (81%) were received (median age, 46 years; 56% males, median follow-up time, 195 months). There was a positive association between age and TF (P < .05), whereas presence of B symptoms at diagnosis and treatment before 1980 were associated with CF. Mean TF scores were elevated in HDSs compared with the GP (mean TF score, 14.6; 95% CI, 14.1 to 15.7 v 12.1; 95% CI, 11.9 to 12.3, respectively; P < .001), as was the proportion of persons with CF (30% v 11%, respectively; odds ratio = 3.6; P < .001). The 70 patients with CF 8 years earlier still reported higher TF at follow-up than the 210 patients without CF at the previous assessment (mean TF score, 17.0; 95% CI, 15.6 to 18.3 v 13.1; 95% CI, 12.9 to 14.1, respectively; P < .001). Significantly more patients with persisting CF had B symptoms at diagnosis compared with patients who had recovered (P = .05). No significant association with treatment modality and intensity was found. CONCLUSION:Fatigue remains a major complaint in HDSs several years after treatment, but the association between treatment and fatigue still remains unclear. Many HDSs may recover from CF, particularly patients without B symptoms at diagnosis.
Authors: Karin Struik; Martin Klein; Jan J Heimans; Marieke F Gielissen; Gijs Bleijenberg; Martin J Taphoorn; Jaap C Reijneveld; Tjeerd J Postma Journal: J Neurooncol Date: 2008-12-09 Impact factor: 4.130
Authors: Amanda M Rach; Valerie McLaughlin Crabtree; Tara M Brinkman; Lonnie Zeltzer; Jordan Gilleland Marchak; Deokumar Srivastava; Brooklee Tynes; Jin-Shei Lai; Leslie L Robison; Gregory T Armstrong; Kevin R Krull Journal: J Cancer Surviv Date: 2016-11-12 Impact factor: 4.442
Authors: Simone Oerlemans; Floortje Mols; Djamila E Issa; J H F M Pruijt; Wim G Peters; Marnix Lybeert; Wobbe Zijlstra; Jan Willem W Coebergh; Lonneke V van de Poll-Franse Journal: Haematologica Date: 2012-08-28 Impact factor: 9.941
Authors: Emily Jo Rajotte; Jean C Yi; K Scott Baker; Lindsey Gregerson; Andréa Leiserowitz; Karen L Syrjala Journal: J Cancer Surviv Date: 2012-01-13 Impact factor: 4.442
Authors: Carrie A Thompson; Karen Mauck; Rachel Havyer; Anjali Bhagra; Henna Kalsi; Sharonne N Hayes Journal: Am J Med Date: 2011-12 Impact factor: 4.965
Authors: Daniel A Mulrooney; Kirsten K Ness; Joseph P Neglia; John A Whitton; Daniel M Green; Lonnie K Zeltzer; Leslie L Robison; Ann C Mertens Journal: Sleep Date: 2008-02 Impact factor: 5.849